Overview

Depakote ER in Borderline Personality Disorder

Status:
Completed

Trial end date:
2005-09-01

Target enrollment:
0

Participant gender:
All

Summary

This study examines the effect of Depakote ER versus placebo in a randomized trial of borderline personality disorder. Patients all participate in DBT therapy and those who are not responsive are assigned to either Depakote ER or placebo for up to 12 weeks. Borderline Personality Symtoms are measured and side-effects are assessed.

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

University of Minnesota
University of Minnesota - Clinical and Translational Science Institute

Collaborators:

Abbott
Schulz, S. Charles, M.D.

Treatments:

Valproic Acid

Criteria

Inclusion Criteria:Male or female patients with the diagnosis of borderline personality
disorder between the ages of 21 adn 55 years old. Must be in good physical health -

Exclusion Criteria:Major psychiatric illness on Axis I - schizophrenia or bipolar disorder.
May not have current MDD. May not be dependent on illicit substances or alcohol.

-